- Home
- PRAX vs EXLS Comparison
PRAX vs EXLS Comparison
Compare PRAX & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | EXLS |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.9B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PRAX | EXLS |
|---|---|---|
| Price | $277.10 | $42.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $373.79 | $53.80 |
| AVG Volume (30 Days) | 580.2K | ★ 1.1M |
| Earning Date | 02-27-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.94 |
| EPS | N/A | ★ 1.48 |
| Revenue | $7,463,000.00 | ★ $2,026,490,000.00 |
| Revenue This Year | N/A | $15.32 |
| Revenue Next Year | $12,467.71 | $11.27 |
| P/E Ratio | ★ N/A | $28.84 |
| Revenue Growth | ★ 364.98 | 14.43 |
| 52 Week Low | $26.70 | $37.30 |
| 52 Week High | $317.72 | $52.43 |
Technical Indicators
Market Signals| Indicator | PRAX | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 52.71 |
| Support Level | $268.78 | $40.71 |
| Resistance Level | $305.21 | $43.17 |
| Average True Range (ATR) | 15.32 | 0.68 |
| MACD | -3.91 | -0.12 |
| Stochastic Oscillator | 20.68 | 48.67 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.